Header Logo

Connection

Renate Strehlau to Humans

This is a "connection" page, showing publications Renate Strehlau has written about Humans.
Connection Strength

1,296
  1. Outcomes of newborn hearing screening at an academic secondary level hospital in Johannesburg, South Africa. S Afr J Commun Disord. 2021 Jan 27; 68(1):e1-e8.
    View in: PubMed
    Score: 0,056
  2. Neurodevelopment in early treated HIV-infected infants participating in a developmental stimulation programme compared with controls. Child Care Health Dev. 2021 03; 47(2):154-162.
    View in: PubMed
    Score: 0,055
  3. Response to Zhao and Zhou: Diagnosis of HIV infection in breastfed infants of mothers on antiretroviral therapy. AIDS. 2020 04 01; 34(5):798-799.
    View in: PubMed
    Score: 0,053
  4. A description of early neurodevelopment in a cohort of HIV-exposed uninfected children. AIDS Care. 2020 11; 32(11):1421-1428.
    View in: PubMed
    Score: 0,052
  5. HIV diagnostic challenges in breast-fed infants of mothers on antiretroviral therapy. AIDS. 2019 09 01; 33(11):1751-1756.
    View in: PubMed
    Score: 0,051
  6. Substituting Abacavir for Stavudine in Children Who Are Virally Suppressed Without Lipodystrophy: Randomized Clinical Trial in Johannesburg, South Africa. J Pediatric Infect Dis Soc. 2018 Aug 17; 7(3):e70-e77.
    View in: PubMed
    Score: 0,047
  7. Neurodevelopmental assessment of HIV-exposed uninfected and early-treated HIV-infected children: study protocol. BMC Res Notes. 2018 Apr 06; 11(1):235.
    View in: PubMed
    Score: 0,046
  8. HIV-associated neurodevelopmental delay: prevalence, predictors and persistence in relation to antiretroviral therapy initiation and viral suppression. Child Care Health Dev. 2016 11; 42(6):881-889.
    View in: PubMed
    Score: 0,041
  9. Developmental status of preschool children receiving cART: a descriptive cohort study. Child Care Health Dev. 2016 May; 42(3):410-4.
    View in: PubMed
    Score: 0,039
  10. PRINCE-1: safety and efficacy of atazanavir powder and ritonavir liquid in HIV-1-infected antiretroviral-naïve and -experienced infants and children aged =3 months to <6 years. J Int AIDS Soc. 2015; 18:19467.
    View in: PubMed
    Score: 0,038
  11. Lipid profiles in young HIV-infected children initiating and changing antiretroviral therapy. J Acquir Immune Defic Syndr. 2012 Aug 01; 60(4):369-76.
    View in: PubMed
    Score: 0,031
  12. Absence seizures associated with efavirenz initiation. Pediatr Infect Dis J. 2011 Nov; 30(11):1001-3.
    View in: PubMed
    Score: 0,029
  13. Pharmacokinetics, safety and efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide in children with HIV aged from 2 years and weighing at least 14 kg. J Int AIDS Soc. 2025 Feb; 28(2):e26414.
    View in: PubMed
    Score: 0,018
  14. Pharmacokinetics and safety of coformulated bictegravir, emtricitabine, and tenofovir alafenamide in children aged 2 years and older with virologically suppressed HIV: a phase 2/3, open-label, single-arm study. Lancet HIV. 2024 May; 11(5):e300-e308.
    View in: PubMed
    Score: 0,017
  15. Infection prevention and control and related practices in African neonatal units: The Pan-African neonatal care assessment study (PANCAS). Int J Hyg Environ Health. 2024 Jun; 259:114357.
    View in: PubMed
    Score: 0,017
  16. Growth Trajectories Over the First Year of Life Among Early-Treated Infants with Human Immunodeficiency Virus and Infants Who are Human Immunodeficiency Virus-Exposed Uninfected. J Pediatr. 2024 Jul; 270:114018.
    View in: PubMed
    Score: 0,017
  17. Higher CCR5 density on CD4 + T-cells in mothers and infants is associated with increased risk of in-utero HIV-1 transmission. AIDS. 2024 06 01; 38(7):945-954.
    View in: PubMed
    Score: 0,017
  18. Potential for Maternally Administered Vaccine for Infant Group B Streptococcus. N Engl J Med. 2023 Jul 20; 389(3):215-227.
    View in: PubMed
    Score: 0,017
  19. Microbiota in the oral cavity of school-age children with HIV who started antiretroviral therapy at young ages in South Africa. AIDS. 2023 08 01; 37(10):1583-1591.
    View in: PubMed
    Score: 0,016
  20. Antepartum SARS-CoV-2 infection and adverse birth outcomes in South African women. J Glob Health. 2022 Dec 03; 12:05050.
    View in: PubMed
    Score: 0,016
  21. Active Intrapartum SARS-CoV-2 Infection and Pregnancy Outcomes. Am J Perinatol. 2022 12; 39(S 01):S42-S48.
    View in: PubMed
    Score: 0,016
  22. Comparison of quantitative ultrasonography and dual X-ray absorptiometry for bone status assessment in South African children living with HIV. PLoS One. 2022; 17(10):e0276290.
    View in: PubMed
    Score: 0,016
  23. FCGR3A gene duplication, Fc?RIIb-232TT and Fc?RIIIb-HNA1a associate with an increased risk of vertical acquisition of HIV-1. PLoS One. 2022; 17(9):e0273933.
    View in: PubMed
    Score: 0,016
  24. Healthy dynamics of CD4 T cells may drive HIV resurgence in perinatally-infected infants on antiretroviral therapy. PLoS Pathog. 2022 08; 18(8):e1010751.
    View in: PubMed
    Score: 0,016
  25. Maternal-foetal transfer of severe acute respiratory syndrome coronavirus 2 antibodies among women with and those without HIV infection. AIDS. 2022 11 01; 36(13):1777-1782.
    View in: PubMed
    Score: 0,015
  26. Predictors of Cell-Associated Human Immunodeficiency Virus (HIV)-1 DNA Over 1 Year in Very Early Treated Infants. Clin Infect Dis. 2022 03 23; 74(6):1047-1054.
    View in: PubMed
    Score: 0,015
  27. An HIV Vaccine Protective Allele in FCGR2C Associates With Increased Odds of Perinatal HIV Acquisition. Front Immunol. 2021; 12:760571.
    View in: PubMed
    Score: 0,015
  28. Persistently lower bone mass and bone turnover among South African children living with well controlled HIV. AIDS. 2021 11 01; 35(13):2137-2147.
    View in: PubMed
    Score: 0,015
  29. Evaluating the performance of the GeneXpert HIV-1 qualitative assay as a consecutive test for a new early infant diagnosis algorithm in South Africa. S Afr Med J. 2021 09 02; 111(9):857-861.
    View in: PubMed
    Score: 0,015
  30. Switch to Efavirenz Attenuates Lipoatrophy in Girls With Perinatal HIV. J Pediatr Gastroenterol Nutr. 2021 01 01; 72(1):e15-e20.
    View in: PubMed
    Score: 0,014
  31. Low Pretreatment Viral Loads in Infants With HIV in an Era of High-maternal Antiretroviral Therapy Coverage. Pediatr Infect Dis J. 2021 01; 40(1):55-59.
    View in: PubMed
    Score: 0,014
  32. Quantifying the Dynamics of HIV Decline in Perinatally Infected Neonates on Antiretroviral Therapy. J Acquir Immune Defic Syndr. 2020 10 01; 85(2):209-218.
    View in: PubMed
    Score: 0,014
  33. Behavioral Functioning and Quality of Life in South African Children Living with HIV on Antiretroviral Therapy. J Pediatr. 2020 12; 227:308-313.e2.
    View in: PubMed
    Score: 0,013
  34. Bone turnover markers in children living with HIV remaining on ritonavir-boosted lopinavir or switching to efavirenz. Bone. 2020 09; 138:115500.
    View in: PubMed
    Score: 0,013
  35. Deficits in Bone Architecture and Strength in Children Living With HIV on Antiretroviral Therapy. J Acquir Immune Defic Syndr. 2020 05 01; 84(1):101-106.
    View in: PubMed
    Score: 0,013
  36. Abacavir Exposure in Children Cotreated for Tuberculosis with Rifampin and Superboosted Lopinavir-Ritonavir. Antimicrob Agents Chemother. 2020 04 21; 64(5).
    View in: PubMed
    Score: 0,013
  37. Negative Diagnostic PCR Tests in School-Aged, HIV-Infected Children on Antiretroviral Therapy Since Early Life in Johannesburg, South Africa. J Acquir Immune Defic Syndr. 2020 04 01; 83(4):381-389.
    View in: PubMed
    Score: 0,013
  38. Bone Quality Measured Using Calcaneal Quantitative Ultrasonography Is Reduced Among Children with HIV in Johannesburg, South Africa. J Pediatr. 2019 12; 215:267-271.e2.
    View in: PubMed
    Score: 0,013
  39. Distinct epigenetic profiles in children with perinatally-acquired HIV on antiretroviral therapy. Sci Rep. 2019 07 19; 9(1):10495.
    View in: PubMed
    Score: 0,013
  40. Mitochondrial Impairment in Well-Suppressed Children with Perinatal HIV-Infection on Antiretroviral Therapy. AIDS Res Hum Retroviruses. 2020 01; 36(1):27-38.
    View in: PubMed
    Score: 0,013
  41. Educational delays among children living with perinatally-acquired HIV in Johannesburg, South Africa. AIDS Care. 2020 04; 32(4):438-444.
    View in: PubMed
    Score: 0,013
  42. Early infant diagnosis HIV-1 PCR cycle-threshold predicts infant viral load at birth. J Clin Virol. 2019 05; 114:21-25.
    View in: PubMed
    Score: 0,012
  43. 12-month outcomes of HIV-infected infants identified at birth at one maternity site in Johannesburg, South Africa: an observational cohort study. Lancet HIV. 2018 12; 5(12):e706-e714.
    View in: PubMed
    Score: 0,012
  44. Biomarkers of Aging in HIV-Infected Children on Suppressive Antiretroviral Therapy. J Acquir Immune Defic Syndr. 2018 08 15; 78(5):549-556.
    View in: PubMed
    Score: 0,012
  45. Patterns of Growth, Body Composition, and Lipid Profiles in a South African Cohort of Human Immunodeficiency Virus-Infected and Uninfected Children: A Cross-Sectional Study. J Pediatric Infect Dis Soc. 2018 May 15; 7(2):143-150.
    View in: PubMed
    Score: 0,012
  46. Age at antiretroviral therapy initiation and cell-associated HIV-1 DNA levels in HIV-1-infected children. PLoS One. 2018; 13(4):e0195514.
    View in: PubMed
    Score: 0,011
  47. Decreased bone turnover in HIV-infected children on antiretroviral therapy. Arch Osteoporos. 2018 Apr 05; 13(1):40.
    View in: PubMed
    Score: 0,011
  48. Reply to Van de Wijer et al. Clin Infect Dis. 2018 03 19; 66(7):1151-1152.
    View in: PubMed
    Score: 0,011
  49. Dietary Inadequacies in HIV-infected and Uninfected School-aged Children in Johannesburg, South Africa. J Pediatr Gastroenterol Nutr. 2017 09; 65(3):332-337.
    View in: PubMed
    Score: 0,011
  50. Prevalence and outcomes of HIV-1 diagnostic challenges during universal birth testing - an urban South African observational cohort. J Int AIDS Soc. 2017 08 29; 20(Suppl 6):21761.
    View in: PubMed
    Score: 0,011
  51. Switching to Efavirenz Versus Remaining on Ritonavir-boosted Lopinavir in Human Immunodeficiency Virus-infected Children Exposed to Nevirapine: Long-term Outcomes of a Randomized Trial. Clin Infect Dis. 2017 Aug 01; 65(3):477-485.
    View in: PubMed
    Score: 0,011
  52. Early age at start of antiretroviral therapy associated with better virologic control after initial suppression in HIV-infected infants. AIDS. 2017 Jan 28; 31(3):355-364.
    View in: PubMed
    Score: 0,011
  53. Effect of Lopinavir and Nevirapine Concentrations on Viral Outcomes in Protease Inhibitor-experienced HIV-infected Children. Pediatr Infect Dis J. 2016 12; 35(12):e378-e383.
    View in: PubMed
    Score: 0,010
  54. Benefits and Risks of Antiretroviral Therapy for Perinatal HIV Prevention. N Engl J Med. 2016 11 03; 375(18):1726-1737.
    View in: PubMed
    Score: 0,010
  55. Efavirenz is associated with higher bone mass in South African children with HIV. AIDS. 2016 10 23; 30(16):2459-2467.
    View in: PubMed
    Score: 0,010
  56. Unusually High Calcaneal Speed of Sound Measurements in Children with Small Foot Size. Ultrasound Med Biol. 2017 01; 43(1):357-361.
    View in: PubMed
    Score: 0,010
  57. Extent of disclosure: what perinatally HIV-infected children have been told about their own HIV status. AIDS Care. 2017 03; 29(3):378-386.
    View in: PubMed
    Score: 0,010
  58. Decreased Vigorous Physical Activity in School-Aged Children with Human Immunodeficiency Virus in Johannesburg, South Africa. J Pediatr. 2016 05; 172:103-9.
    View in: PubMed
    Score: 0,010
  59. Case report: Severe central nervous system manifestations associated with aberrant efavirenz metabolism in children: the role of CYP2B6 genetic variation. BMC Infect Dis. 2016 Feb 02; 16:56.
    View in: PubMed
    Score: 0,010
  60. Efavirenz-Based Antiretroviral Therapy Among Nevirapine-Exposed HIV-Infected Children in South Africa: A Randomized Clinical Trial. JAMA. 2015 Nov 03; 314(17):1808-17.
    View in: PubMed
    Score: 0,010
  61. Genetic Changes in HIV-1 Gag-Protease Associated with Protease Inhibitor-Based Therapy Failure in Pediatric Patients. AIDS Res Hum Retroviruses. 2015 Aug; 31(8):776-82.
    View in: PubMed
    Score: 0,009
  62. Young age at start of antiretroviral therapy and negative HIV antibody results in HIV-infected children when suppressed. AIDS. 2015 Jun 01; 29(9):1053-60.
    View in: PubMed
    Score: 0,009
  63. Concordance between allele-specific PCR and ultra-deep pyrosequencing for the detection of HIV-1 non-nucleoside reverse transcriptase inhibitor resistance mutations. J Virol Methods. 2014 Oct; 207:182-7.
    View in: PubMed
    Score: 0,009
  64. Timing of maternal HIV testing and uptake of prevention of mother-to-child transmission interventions among women and their infected infants in Johannesburg, South Africa. J Acquir Immune Defic Syndr. 2014 Apr 15; 65(5):e170-8.
    View in: PubMed
    Score: 0,009
  65. Plasma lopinavir concentrations predict virological failure in a cohort of South African children initiating a protease-inhibitor-based regimen. Antivir Ther. 2014; 19(4):399-406.
    View in: PubMed
    Score: 0,009
  66. Sex differences in responses to antiretroviral treatment in South African HIV-infected children on ritonavir-boosted lopinavir- and nevirapine-based treatment. BMC Pediatr. 2014 Feb 12; 14:39.
    View in: PubMed
    Score: 0,009
  67. Poor early virologic performance and durability of abacavir-based first-line regimens for HIV-infected children. Pediatr Infect Dis J. 2013 Aug; 32(8):851-5.
    View in: PubMed
    Score: 0,008
  68. Adherence and viral suppression among infants and young children initiating protease inhibitor-based antiretroviral therapy. Pediatr Infect Dis J. 2013 May; 32(5):489-94.
    View in: PubMed
    Score: 0,008
  69. Initiation of antiretroviral therapy before 6 months of age is associated with faster growth recovery in South African children perinatally infected with human immunodeficiency virus. J Pediatr. 2013 Jun; 162(6):1138-45, 1145.e1-2.
    View in: PubMed
    Score: 0,008
  70. Metabolic abnormalities and body composition of HIV-infected children on Lopinavir or Nevirapine-based antiretroviral therapy. Arch Dis Child. 2013 Apr; 98(4):258-64.
    View in: PubMed
    Score: 0,008
  71. Switching children previously exposed to nevirapine to nevirapine-based treatment after initial suppression with a protease-inhibitor-based regimen: long-term follow-up of a randomised, open-label trial. Lancet Infect Dis. 2012 Jul; 12(7):521-30.
    View in: PubMed
    Score: 0,008
  72. Rapid development of antiretroviral drug resistance mutations in HIV-infected children less than two years of age initiating protease inhibitor-based therapy in South Africa. AIDS Res Hum Retroviruses. 2011 Sep; 27(9):945-56.
    View in: PubMed
    Score: 0,007
  73. Induction therapy with protease-inhibitors modifies the effect of nevirapine resistance on virologic response to nevirapine-based HAART in children. Clin Infect Dis. 2011 Feb 15; 52(4):514-21.
    View in: PubMed
    Score: 0,007
  74. Initial response to protease-inhibitor-based antiretroviral therapy among children less than 2 years of age in South Africa: effect of cotreatment for tuberculosis. J Infect Dis. 2010 Apr 15; 201(8):1121-31.
    View in: PubMed
    Score: 0,007
  75. Immune reconstitution inflammatory syndrome among HIV-infected South African infants initiating antiretroviral therapy. AIDS. 2009 Jun 01; 23(9):1097-107.
    View in: PubMed
    Score: 0,006
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.